Subscribe to NRx Newsletter

Nephron Pharmaceuticals

CEO Update: Update on ZYESAMI™ (aviptadil) Manufacturing Efforts

NRx is pleased to announce that last week a revised Investigational New Drug module on the manufacturing of ZYESAMI™ (aviptadil) was submitted to the US Food and Drug Administration (FDA), containing documentation that confirmed Nephron Pharmaceuticals, Inc. is prepared to supply ZYESAMI on a commercial scale. This module will now be used as part of […]